BB Biotech

EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share

Retrieved on: 
Wednesday, April 10, 2024
CHF, BB Biotech, Annual general meeting, Holding company

Media release of March 21, 2024

Key Points: 
  • Media release of March 21, 2024
    All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today.
  • Shareholders voted in favor of the proposal to pay out a dividend of CHF 2.00 gross per share.
  • Payment will be made on March 27, 2024, the record date is March 26, 2024 and the ex-dividend date is March 25, 2024.
  • The Board of Directors thanks him for his valuable contribution and personal commitment to BB Biotech over the past 13 years.

EQS-News: Abivax reports 2023 financial results and operational update

Retrieved on: 
Wednesday, April 10, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Abivax reports 2023 financial results and operational update

Retrieved on: 
Tuesday, April 2, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

Retrieved on: 
Thursday, March 28, 2024
Stifel, BB Biotech, Exchange, Sale, Cancer, Security (finance), Therapy

The financing is being led by existing investor BVF Partners L.P. and includes existing investors BB Biotech AG and Santé, and other leading institutional investors.

Key Points: 
  • The financing is being led by existing investor BVF Partners L.P. and includes existing investors BB Biotech AG and Santé, and other leading institutional investors.
  • The closing of the second tranche is subject to the satisfaction of customary closing conditions.
  • MTEM intends to use the net proceeds from the proceeds of the second tranche to fund its ongoing clinical studies, working capital and for general corporate purposes.
  • MTEM has agreed to file a resale registration statement with the Securities and Exchange Commission registering the resale of the securities issued in the second tranche.

EQS-News: Investor interest returns – dividend yield remains high for 2024

Retrieved on: 
Wednesday, February 14, 2024
Acquisition, Annual general meeting, RSV, USD, Cystic fibrosis, Ionis, FDA, Pain, Patient, Policy, BB Biotech, Alnylam Pharmaceuticals, Depression, Pharmaceutical industry

Release as at February 14, 2024

Key Points: 
  • Release as at February 14, 2024
    After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest.
  • The prospect of falling interest rates has led to a rethink.
  • A dividend of this magnitude is exceptional not just in the Swiss equity market, but also in an international comparison.
  • Experts are anticipating similarly high approval figures for 2024 too.

EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle

Retrieved on: 
Tuesday, January 30, 2024
Neuroscience, Patient, Annual general meeting, United States dollar, Research, ADC, Health care, Policy, Biotechnology, NAV, Dax, Intelligence, Annual, SGA, BB Biotech, AGM, Euro, Investment, Hereditary angioedema, EQT, Consolidated, Lifting, Hunziker, CHF, Affibody molecule, Thalassemia, Annual report, Clinical trial, MSCI, Cardiomyopathy, Revolution, Pharmaceutical industry

Media release as at January 19, 2024

Key Points: 
  • Media release as at January 19, 2024
    Portfolio of BB Biotech AG as at December 31, 2023
    In 2023, global equity performed better than anticipated by many.
  • Consequently, BB Biotech ended the year with a net loss of CHF 207 mn.
  • This represents a 5% return based on the volume-weighted average closing price of BB Biotech shares in December 2023.
  • The US central bank held rates steady in the fall, lifting market sentiment in the last two months of 2023.

Arvinas Announces Oversubscribed $350 Million Private Placement

Retrieved on: 
Monday, November 27, 2023
Citadel, Goldman Sachs, Sale, LP, BofA Securities, Investment, ARVN, Prospectus, BB Biotech, Exercise, Security (finance)

The aggregate gross proceeds from the offering are expected to be approximately $350 million, before deducting placement agent fees and offering expenses.

Key Points: 
  • The aggregate gross proceeds from the offering are expected to be approximately $350 million, before deducting placement agent fees and offering expenses.
  • The private placement is expected to close on or about November 28, 2023, subject to the satisfaction of customary closing conditions.
  • BofA Securities, Inc. and Goldman Sachs & Co. LLC acted as joint lead placement agents to Arvinas in connection with the private placement.
  • Arvinas has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement no later than the 30th day after the closing of the private placement.

EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Retrieved on: 
Thursday, October 26, 2023
Neoplasm, FDA, Federal Trade Commission, HHS, Attention, Chronic inflammatory demyelinating polyneuropathy, Ovarian cancer, Frankfurt Stock Exchange, NASDAQ Biotechnology Index, Government, Obesity, Fundamental, DSM-IV codes, Alnylam Pharmaceuticals, CAH, Neurocrine, Posture, SIX Swiss Exchange, Office of Inspector General, U.S. Department of Health and Human Services, Zuranolone, Congenital adrenal hyperplasia, Biotechnology, Inflation Reduction Act of 2022, Hypertension, NBI, Amgen, NET, Depression, BB Biotech, Platinum, NAV, CIDP, Woman, FTC, Inflation, Investment, Therapy, Patient, Cabozantinib, CHF, POC, Security (finance), Rare-earth element, Public utility, Pharmaceutical industry, Bank, Vertex, Incyte, EUR, USD, Valbenazine

BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Key Points: 
  • BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
    The issuer is solely responsible for the content of this announcement.
  • The rise in bond yields weighed heavily on biotech stocks as well as the stock market in general.
  • BB Biotech benefited from the dollar's appreciation, but it was also exposed to the sustained selling pressure on equity markets.
  • BB Biotech traded within a narrow range during the third quarter, closing slightly higher at CHF 41.35 per share.

EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry

Retrieved on: 
Friday, July 21, 2023
Diamond, Pressure, SIX Swiss Exchange, Hyperglycemia, BB Biotech, Insulin, CMS, Investment, Diarrhea, Net asset value, Frankfurt Stock Exchange, Politics, Biogen, Biotechnology, Policy, Dow Jones, Survival, Clinical trial, Diabetes, NAV, NSCLC, Lung cancer, Rash, Ionis, PI3K, US, Inflation, Agios, SOD1, Patient, FTSE Italia Mid Cap, EGFR, NBI, United States dollar, Sickle cell disease, Merck, Inflation Reduction Act of 2022, Neoplasm, FDA, Therapy, CHF, News, ALS, BB, Pharmaceutical industry, Cryptocurrency, Bank, Vertex, Efgartigimod alfa, USD, EUR, Pembrolizumab

BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry

Key Points: 
  • BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
    The issuer is solely responsible for the content of this announcement.
  • Media release as at July 21, 2023
    Interim report of BB Biotech AG as at June 30, 2023
    Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
    The first half of 2023 has been disappointing for biotech investors.
  • This delisting will lower BB Biotech’s administrative costs and BB Biotech shareholders will still be able to buy and sell BB Biotech shares in EUR on the Frankfurt Stock Exchange.
  • The quarterly report of BB Biotech AG as at June 30, 2023, can be downloaded at report.bbbiotech.ch/Q223 or www.bbbiotech.com .

Molecular Templates Announces Up to $40 Million Private Placement Offering

Retrieved on: 
Thursday, July 13, 2023
BB Biotech, Therapy, Stifel, Cancer, Exchange, Sale, Adage Capital Management, Bangladesh Securities and Exchange Commission, Security (finance), BMS, Pharmaceutical industry

The financing is being led by existing investor BVF Partners LP and includes existing investors BB Biotech AG and Adage Capital Management, and other leading institutional investors.

Key Points: 
  • The financing is being led by existing investor BVF Partners LP and includes existing investors BB Biotech AG and Adage Capital Management, and other leading institutional investors.
  • The first tranche is expected to close on July 17, 2023, subject to the satisfaction of customary closing conditions.
  • Stifel is acting as the sole placement agent in connection with the financing.
  • MTEM intends to use the net proceeds from the private placement to fund its ongoing clinical studies, working capital and for general corporate purposes and to continue its collaboration activities with BMS.